Floatz logo

Pembrolizumab

Recurrent Glioblastoma, IDH-Wildtype

Mayo Clinicmonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Recurrent Glioblastoma, IDH-Wildtype cohort.

Asset / SponsorPhaseRating
Epirubicin
Mayo Clinic
Phase 2B
Cyclophosphamide
Mayo Clinic
Phase 2B
Cerebraca Wafer
Everfront Biotech Co., Ltd.
Phase 2/3B
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC
Tiragolumab
National Cancer Institute (NCI)
Phase 2CCC

View all 11 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →